Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at evaluere effektiviteten og sikkerheden af ​​Frexalimab, SAR442970 eller Rilzabrutinib hos deltagere i alderen 16 til 75 år med primær fokal segmentel glomerulosklerose eller minimal forandringssygdom (RESULT)

9. november 2026 opdateret af: Sanofi

En parallelgruppebehandling, fase 2a, multicenter, randomiseret, dobbeltblind, placebokontrolleret paraplyundersøgelse til evaluering af effektiviteten og sikkerheden af ​​Frexalimab, SAR442970 og Rilzabrutinib hos deltagere i alderen 16 til 75 år med primær fokal glomerulos segmental glomerulos (FSGS) eller Minimal Change Disease (MCD)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).

The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig or rilzabrutinib compared with placebo in participants with primary FSGS or MCD aged 16 to 75 years.

Study details for each participant include:

The study duration will be up to 52 weeks. The treatment duration will be 24 weeks. There will be up to 16 visits.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

84

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Trial Transparency email recommended (Toll free for US & Canada)
  • Telefonnummer: option 6 800-633-1610
  • E-mail: contact-us@sanofi.com

Studiesteder

      • Buenos Aires, Argentina, 1431
        • Rekruttering
        • Investigational Site Number : 0320001
      • Córdoba, Argentina, 5016
        • Rekruttering
        • Investigational Site Number : 0320002
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australien, 2605
        • Rekruttering
        • Investigational Site Number : 0360003
    • Victoria
      • Parkville, Victoria, Australien, 3050
        • Rekruttering
        • Investigational Site Number : 0360001
      • São Paulo, Brasilien, 05403-000
        • Rekruttering
        • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760001
      • São Paulo, Brasilien, 04038-002
        • Rekruttering
        • Hospital do Rim e Hipertensão- Site Number : 0760002
    • São Paulo
      • Botucatu, São Paulo, Brasilien, 18618-970
        • Rekruttering
        • Universidade Estadual Paulista - Faculdade de Medicina de Botucatu- Site Number : 0760004
      • São Paulo, São Paulo, Brasilien, 01139-000
        • Rekruttering
        • Synvia Clinical- Site Number : 0760005
    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • Rekruttering
        • Investigational Site Number : 1240002
      • Toronto, Ontario, Canada, M5G 1X8
        • Rekruttering
        • Investigational Site Number : 1240004
    • Quebec
      • Montreal, Quebec, Canada, H1T 2M4
        • Rekruttering
        • Investigational Site Number : 1240001
      • Montreal, Quebec, Canada, H3T 1C5
        • Rekruttering
        • Investigational Site Number : 1240005
      • Québec, Quebec, Canada, G1R 2J6
        • Rekruttering
        • Investigational Site Number : 1240006
    • La Araucanía
      • Temuco, La Araucanía, Chile, 4781151
        • Rekruttering
        • Investigational Site Number : 1520003
    • Reg Metropolitana de Santiago
      • Santiago, Reg Metropolitana de Santiago, Chile, 8330034
        • Rekruttering
        • Investigational Site Number : 1520002
    • Leicestershire
      • Leicester, Leicestershire, Det Forenede Kongerige, LE5 4PW
        • Rekruttering
        • Investigational Site Number : 8260001
    • Manchester
      • Salford, Manchester, Det Forenede Kongerige, M6 8HD
        • Rekruttering
        • Investigational Site Number : 8260004
    • Oxfordshire
      • Oxford, Oxfordshire, Det Forenede Kongerige, OX3 7LE
        • Rekruttering
        • Investigational Site Number : 8260005
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Rekruttering
        • University of Alabama -The Kirklin Clinic- Site Number : 8400007
    • California
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • University of California Irvine Medical Center- Site Number : 8400015
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • University of California San Francisco - Parnassus Heights- Site Number : 8400012
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • University Of South Florida - Parent- Site Number : 8400025
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory Children's Center- Site Number : 8400020
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern Memorial Hospital- Site Number : 8400014
      • Hinsdale, Illinois, Forenede Stater, 60521
        • Rekruttering
        • Nephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale- Site Number : 8400017
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan Health System - Ann Arbor- Site Number : 8400010
    • Minnesota
      • Edina, Minnesota, Forenede Stater, 55435
        • Rekruttering
        • InterMed Consultants - Edina Clinic- Site Number : 8400019
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89107
        • Aktiv, ikke rekrutterende
        • DaVita Clinical Research - Las Vegas - North Rainbow Boulevard- Site Number : 8400018
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87109
        • Rekruttering
        • Renal Medicine Associates- Site Number : 8400028
    • New York
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • Columbia University Irving Medical Center- Site Number : 8400001
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • The Children's Hospital at Montefiore- Site Number : 8400027
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27599
        • Rekruttering
        • UNC Kidney Center- Site Number : 8400021
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic - Cleveland- Site Number : 8400029
    • Texas
      • Dallas, Texas, Forenede Stater, 75204
        • Rekruttering
        • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400024
      • El Paso, Texas, Forenede Stater, 79902
        • Rekruttering
        • El Paso Kidney Specialists- Site Number : 8400005
      • Houston, Texas, Forenede Stater, 77054
        • Rekruttering
        • Prolato Clinical Research Center- Site Number : 8400016
      • Créteil, Frankrig, 94010
        • Rekruttering
        • Investigational Site Number : 2500002
      • Paris, Frankrig, 75015
        • Rekruttering
        • Investigational Site Number : 2500001
      • Athens, Grækenland, 115 27
        • Rekruttering
        • Investigational Site Number : 3000002
      • Heraklion, Grækenland, 711 10
        • Rekruttering
        • Investigational Site Number : 3000001
      • Ioannina, Grækenland, 455 00
        • Rekruttering
        • Investigational Site Number : 3000003
      • Amsterdam, Holland, 1105 AZ
        • Rekruttering
        • Investigational Site Number : 5280001
      • Brescia, Italien, 25123
        • Rekruttering
        • Investigational Site Number : 3800001
    • Firenze
      • Florence, Firenze, Italien, 50134
        • Rekruttering
        • Investigational Site Number : 3800002
    • Milano
      • Monza, Milano, Italien, 20900
        • Rekruttering
        • Investigational Site Number : 3800004
    • Napoli
      • Naples, Napoli, Italien, 80131
        • Rekruttering
        • Investigational Site Number : 3800003
      • Beijing, Kina, 100034
        • Rekruttering
        • Investigational Site Number : 1560001
      • Chengdu, Kina, 610072
        • Rekruttering
        • Investigational Site Number : 1560003
      • Shanghai, Kina, 200080
        • Afsluttet
        • Investigational Site Number : 1560004
    • Mexico City
      • Mexico City, Mexico City, Mexico, 14080
        • Rekruttering
        • Investigational Site Number : 4840001
      • Mexico City, Mexico City, Mexico, 06720
        • Rekruttering
        • Investigational Site Number : 4840005
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64460
        • Rekruttering
        • Investigational Site Number : 4840003
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 60-780
        • Rekruttering
        • Investigational Site Number : 6160004
    • Lódzkie
      • Lodz, Lódzkie, Polen, 02-213
        • Rekruttering
        • Investigational Site Number : 6160001
    • Opole Voivodeship
      • Opole, Opole Voivodeship, Polen, 45-418
        • Rekruttering
        • Investigational Site Number : 6160002
      • Carnaxide, Portugal, 2790-134
        • Rekruttering
        • Investigational Site Number : 6200004
      • Lisbon, Portugal, 1050-099
        • Rekruttering
        • Investigational Site Number : 6200003
      • Matosinhos Municipality, Portugal, 4464-513
        • Afsluttet
        • Investigational Site Number : 6200001
      • Porto, Portugal, 4434-502
        • Rekruttering
        • Investigational Site Number : 6200002
      • Banská Bystrica, Slovakiet, 975 17
        • Rekruttering
        • Investigational Site Number : 7030003
      • Bratislava - Kramare, Slovakiet, 831 01
        • Rekruttering
        • Investigational Site Number : 7030004
      • Martin, Slovakiet, 036 01
        • Rekruttering
        • Investigational Site Number : 7030001
      • Córdoba, Spanien, 14004
        • Rekruttering
        • Investigational Site Number : 7240002
      • Madrid, Spanien, 28007
        • Rekruttering
        • Investigational Site Number : 7240008
      • Madrid, Spanien, 28040
        • Rekruttering
        • Investigational Site Number : 7240007
      • Valencia, Spanien, 46026
        • Afsluttet
        • Investigational Site Number : 7240003
    • Andalusia
      • Seville, Andalusia, Spanien, 41013
        • Rekruttering
        • Investigational Site Number : 7240005
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Spanien, 08035
        • Rekruttering
        • Investigational Site Number : 7240001
      • Barcelona, Catalunya [Cataluña], Spanien, 08025
        • Afsluttet
        • Investigational Site Number : 7240004
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Rekruttering
        • Investigational Site Number : 7240009
      • Taichung, Taiwan, 404
        • Rekruttering
        • Investigational Site Number : 1580001
      • Taipei, Taiwan, 100
        • Rekruttering
        • Investigational Site Number : 1580002
      • Olomouc, Tjekkiet, 779 00
        • Rekruttering
        • Investigational Site Number : 2030002
      • Prague, Tjekkiet, 128 08
        • Rekruttering
        • Investigational Site Number : 2030001
      • Kayseri, Tyrkiet (Türkiye), 38039
        • Rekruttering
        • Investigational Site Number : 7920002
      • İzmit, Tyrkiet (Türkiye), 41001
        • Rekruttering
        • Investigational Site Number : 7920001
      • Berlin, Tyskland, 10117
        • Rekruttering
        • Investigational Site Number : 2760002
      • Dresden, Tyskland, 01307
        • Rekruttering
        • Investigational Site Number : 2760006
      • Hanover, Tyskland, 30625
        • Rekruttering
        • Investigational Site Number : 2760003
      • Budapest, Ungarn, 1085
        • Rekruttering
        • Investigational Site Number : 3480001
      • Pécs, Ungarn, 7624
        • Rekruttering
        • Investigational Site Number : 3480005
      • Szeged, Ungarn, 6725
        • Rekruttering
        • Investigational Site Number : 3480006

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

16 år til 75 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Biopsy report indicative of primary FSGS or MCD, with supportive clinical presentation per Investigator's judgement.
  • UPCR ≥3 g/g at screening, or ≥ 1.5 g/g in those with eGFR ≥ 60 mL/min/1.73 m2.
  • eGFR ≥45 mL/min/1.73 m^2 at screening.
  • Documented history of UPCR or UACR (or 24-hour urine protein or 24-hour urine albumin) reduction by >40% in response to corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was ≥3.5 g/g or equivalent for UACR (or pre-treatment 24-hr urine protein was ≥3.5 g/day if 24-hour urine protein is used or equivalent for 24-hr urine albumin if 24-hour urine albumin is used).
  • ≤10 mg/day prednisone or equivalent and stable starting at least 1 week prior to randomization.
  • For those on a RAAS inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting RAAS inhibitors or changing the dose will not be allowed during the double-blind or OLE treatment period.
  • For those on an SGLT2 inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting SGLT2 inhibitor treatment or changing the dose will not be allowed during the double-blind or OLE treatment periods.
  • Body weight within 45 to 120 kg (inclusive) at screening.

Exclusion Criteria:

  • Genetic or secondary FSGS or MCD. Those with APOL1 risk alleles are eligible.
  • Collapsing variant of FSGS.
  • ESKD requiring dialysis or transplantation.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Matching placebo

placebo treatment

Eksperimentel: Frexalimab

Frexalimab active dose

frexalimab treatment

Eksperimentel: Brivekimig

Brivekimig active dose

brivekimig treatment

Eksperimentel: Rilzabrutinib

Rilzabrutinib active dose

rilzabrutinib treatment

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Procent reduktion i urinprotein til kreatinin ratio (UPCR)
Tidsramme: Fra baseline til uge 12
Fra baseline til uge 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Plasmakoncentrationer af frexalimab og rilzabrutinib og serumkoncentrationer af SAR442970
Tidsramme: Op til uge 48
Op til uge 48
Forekomst af anti-lægemiddel-antistoffer (ADA'er) mod frexalimab og SAR442970
Tidsramme: Op til uge 48
Op til uge 48
Percentage of participants achieving FSGS partial remission endpoint
Tidsramme: At Week 12

Defined as UPCR ≤1.5 g/g and >40 % reduction of UPCR from baseline

At Week 12
Percentage of participants achieving CR
Tidsramme: At Week 12

Defined as UPCR ≤0.3 g/g

At Week 12
Incidence of treatment-emergent adverse events, treatment-emergent serious adverse events (SAEs), treatment-emergent adverse events of special interest (AESIs) and IMP discontinuation due to TEAEs during the study
Tidsramme: Treatment emergent period, up to Week 48

TEAEs, including clinically significant changes in vital signs, electrocardiogram [ECG], and laboratory evaluation

Treatment emergent period, up to Week 48

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. december 2024

Primær færdiggørelse (Anslået)

23. december 2026

Studieafslutning (Anslået)

16. februar 2028

Datoer for studieregistrering

Først indsendt

8. juli 2024

Først indsendt, der opfyldte QC-kriterier

8. juli 2024

Først opslået (Faktiske)

15. juli 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ACT18064
  • 2024-511775-15 (Registry Identifier: CTIS)
  • U1111-1301-2676 (Registry Identifier: WHO)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner